Alteogen
| Market cap | ₩18.1T |
| PE ratio | 95.10 |
| Forward PE | 59.70 |
| PB ratio | 34.00 |
| EPS | ₩2,734 |
| Dividend (yield) | ₩285 (0.11%) |
| Analysts (1–5) | 4.00 · Buy |
| Price target | ₩438,000 (+68.46%) |
| Volume | 238,618 |
| Trading value | ₩62.2B |
| Day’s range | ₩256,500 – ₩266,500 |
| 52-week range | ₩194,671 – ₩437,818 |
| Foreign ownership KR | 15.39% |
| Foreign net buy (Oct 2) KR | −29,053 sh |
| Book value / share | ₩7,646 |
| Founded | 2008 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 2 | ₩259,500 | −29,053 | −12,093 | +41,343 | 15.39% |
| Oct 1 | ₩265,000 | +14,359 | +146,756 | −161,186 | 15.48% |
| Sep 30 | ₩254,500 | +41,422 | +16,230 | −55,726 | 15.46% |
| Sep 29 | ₩253,500 | +14,870 | +31,806 | −47,055 | 15.47% |
| Sep 28 | ₩252,500 | −12,947 | +20,848 | −8,388 | 15.52% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩96.5B | ₩102.9B | ₩215.9B | ₩492.4B |
| Operating income | −₩9.7B | ₩25.4B | ₩106.9B | ₩312.7B |
| Net income | −₩3.6B | ₩60.7B | ₩145.2B | ₩312.9B |
| Operating margin | −10.09% | 24.70% | 49.52% | 63.50% |
| Return on equity | −2.27% | 29.52% | 39.42% | 51.62% |
| Debt-to-equity | 73.23% | 49.23% | 53.76% | – |
| EPS | −₩49 | ₩901 | ₩2,026 | ₩4,355 |
| Dividend per share | – | – | ₩285 | ₩334 |
Peers
| Peptron 087010 | ₩130,600 | +0.85% |
| ABL Bio 298380 | ₩52,500 | +2.14% |
| Hugel 145020 | ₩181,500 | +0.78% |
| D&D Pharmatech 347850 | ₩47,550 | +10.58% |
| Aimed Bio 0009K0 | ₩25,800 | +4.03% |
| Naturecell 007390 | ₩24,750 | 0.00% |
About
Alteogen develops and sells biopharmaceuticals based on platform technologies: Hybrozyme, which turns intravenous drugs into subcutaneous injections, NexP fusion for long-acting biologics, and NexMab for next-generation antibody-drug conjugates. It has licensing deals with global drugmakers such as MSD, AstraZeneca, Sanofi and GSK, earning upfront payments, milestones and royalties. Founded in 2008, it listed on the KOSDAQ in 2014.
Alteogen Inc. is listed on the KOSDAQ market of the Korea Exchange under the ticker 196170. Industry: Research & development.
Alteogen in our notes
- KOSPI Held 7,000 Today, But Watch One Thing Tomorrow Morning
- Daewoo E&C jumps 8.47%, Samsung Electro-Mechanics falls 5.78% as KOSPI slips 0.58%
- Doosan Enerbility jumps 10.98%, SK Hynix 8.26% as the KOSPI adds 4.61% in a single session
- Buybacks Lifted KOSPI 0.23% While KOSDAQ Fell 1.56%
- Rate-hike odds fall from 63% to 50%, and chip and robot stocks carry the KOSPI up 1.64%
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange regular-session closing prices, volume and day’s range via Daum Finance, checked against a Naver Finance snapshot at the close; investor flows, foreign ownership and ratios via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios as of Oct 6, 2026; investor flows as of Oct 2, 2026. Delayed data, not investment advice.